Clinical trial · no report yet · Phase 2
MDT-BRIDGE
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
- NCT05925530 ↗
- Active not recruiting
- AstraZeneca
- 88 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 67 | |
| YouTube | 12 | |
| Podcasts | 8 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab
- Arms
- Durvalumab · Experimental
- Enrollment
- 142
- Primary outcomes
- Resection rate
- Sponsor
- AstraZeneca
- Start
- Feb 22, 2024
- Primary completion
- Jan 12, 2026
- Results posted
- No
- Registry record
- NCT05925530 · updated Sep 9, 2026